Skip to main content
Premium Trial:

Request an Annual Quote

Takeda Licenses CellCentric's Technologies

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Takeda Pharmaceutical Company has licensed from CellCentric cancer-related epigenetic target technologies for development and commercialization.

Under the agreement, Takeda's Research Group will conduct therapeutic research on molecules that will be further developed by Millenium, the biopharmaceutical firm that Takeda acquired in 2008.

The agreement includes an up-front payment, clinical and pre-clinical milestones, and royalties. Overall, the pact could reap as much as $200 million for CellCentric over the course of the agreement.

The CellCentric technology is based on epigenetic alterations caused by a range of enzymes that can be targeted and may be of use in cancer treatment, including histone methyltranserases, demethylases, and ubiquitin-related enzymes.

CellCentric CEO Will West said in a statement that epigenetics "is an area that is no longer seen as just interesting, but as a necessity for pharmaceutical companies growing their armory for tackling intractable diseases such as cancer."

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.